In Situ Vein Bypass Is Superior to Endovascular Treatment of Femoropopliteal Lesions in Chronic Limb-Threatening Ischemia

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

In Situ Vein Bypass Is Superior to Endovascular Treatment of Femoropopliteal Lesions in Chronic Limb-Threatening Ischemia. / Lawaetz, Martin; Fisker, Lasse; Lönn, Lars; Sillesen, Henrik; Eiberg, Jonas.

I: Annals of Vascular Surgery, Bind 67, 2020, s. 437-447.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Lawaetz, M, Fisker, L, Lönn, L, Sillesen, H & Eiberg, J 2020, 'In Situ Vein Bypass Is Superior to Endovascular Treatment of Femoropopliteal Lesions in Chronic Limb-Threatening Ischemia', Annals of Vascular Surgery, bind 67, s. 437-447. https://doi.org/10.1016/j.avsg.2020.03.035

APA

Lawaetz, M., Fisker, L., Lönn, L., Sillesen, H., & Eiberg, J. (2020). In Situ Vein Bypass Is Superior to Endovascular Treatment of Femoropopliteal Lesions in Chronic Limb-Threatening Ischemia. Annals of Vascular Surgery, 67, 437-447. https://doi.org/10.1016/j.avsg.2020.03.035

Vancouver

Lawaetz M, Fisker L, Lönn L, Sillesen H, Eiberg J. In Situ Vein Bypass Is Superior to Endovascular Treatment of Femoropopliteal Lesions in Chronic Limb-Threatening Ischemia. Annals of Vascular Surgery. 2020;67:437-447. https://doi.org/10.1016/j.avsg.2020.03.035

Author

Lawaetz, Martin ; Fisker, Lasse ; Lönn, Lars ; Sillesen, Henrik ; Eiberg, Jonas. / In Situ Vein Bypass Is Superior to Endovascular Treatment of Femoropopliteal Lesions in Chronic Limb-Threatening Ischemia. I: Annals of Vascular Surgery. 2020 ; Bind 67. s. 437-447.

Bibtex

@article{f076d9e6d5ec4b1ea3b66561c618b9c7,
title = "In Situ Vein Bypass Is Superior to Endovascular Treatment of Femoropopliteal Lesions in Chronic Limb-Threatening Ischemia",
abstract = "Background: The objective of the study was to compare bypass surgery and endovascular revascularization of the femoropopliteal segment in patients with peripheral arterial disease and critical limb-threatening ischemia (CLTI). Methods: This is a single-center study including patients undergoing first-time lower extremity intervention with peripheral bypass surgery or percutaneous transluminal angioplasty with or without stenting (PTA/S) of the femoropopliteal segment because of CLTI from 2011 to 2015. Based on prospective entered data from the Danish Vascular Registry, the primary end points were amputation-free survival, overall mortality, and reinterventions. Results: A total of 679 patients with CLTI were included of which 35% (n = 239) were treated with PTA/S, 54% (n = 363) with vein bypass, and 11% (n = 77) with synthetic bypass. After 3 years, amputation-free survival was significantly better with a vein bypass (41.8% [95% CI: 35–48.4]) than both PTA/S (29.7% (95% CI: 22.7–37)) and synthetic bypass (31.7% [95% CI: 19–45.1]). Overall, the endovascular-treated patients faced more than 50% increased risk of major amputation or death than that of a vein bypass, after adjusting for comorbidity and Trans-Atlantic Inter-Society Consensus (TASC) classification (HR: 1.56 [95% CI: 1.21–2.05]). As expected, postoperative complications, length of hospital stay, and reinterventions were more frequent in the bypass groups. Conclusions: In this nonrandomized study, autologous vein bypass was superior to both PTA/S and synthetic bypass in regard to amputation-free survival and overall mortality. Despite the increased frequency of surgical complications, a vein bypass appears justified in both shorter (TASC B-C) and longer (TASC D) femoropopliteal lesions.",
author = "Martin Lawaetz and Lasse Fisker and Lars L{\"o}nn and Henrik Sillesen and Jonas Eiberg",
year = "2020",
doi = "10.1016/j.avsg.2020.03.035",
language = "English",
volume = "67",
pages = "437--447",
journal = "Annals of Vascular Surgery",
issn = "0890-5096",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - In Situ Vein Bypass Is Superior to Endovascular Treatment of Femoropopliteal Lesions in Chronic Limb-Threatening Ischemia

AU - Lawaetz, Martin

AU - Fisker, Lasse

AU - Lönn, Lars

AU - Sillesen, Henrik

AU - Eiberg, Jonas

PY - 2020

Y1 - 2020

N2 - Background: The objective of the study was to compare bypass surgery and endovascular revascularization of the femoropopliteal segment in patients with peripheral arterial disease and critical limb-threatening ischemia (CLTI). Methods: This is a single-center study including patients undergoing first-time lower extremity intervention with peripheral bypass surgery or percutaneous transluminal angioplasty with or without stenting (PTA/S) of the femoropopliteal segment because of CLTI from 2011 to 2015. Based on prospective entered data from the Danish Vascular Registry, the primary end points were amputation-free survival, overall mortality, and reinterventions. Results: A total of 679 patients with CLTI were included of which 35% (n = 239) were treated with PTA/S, 54% (n = 363) with vein bypass, and 11% (n = 77) with synthetic bypass. After 3 years, amputation-free survival was significantly better with a vein bypass (41.8% [95% CI: 35–48.4]) than both PTA/S (29.7% (95% CI: 22.7–37)) and synthetic bypass (31.7% [95% CI: 19–45.1]). Overall, the endovascular-treated patients faced more than 50% increased risk of major amputation or death than that of a vein bypass, after adjusting for comorbidity and Trans-Atlantic Inter-Society Consensus (TASC) classification (HR: 1.56 [95% CI: 1.21–2.05]). As expected, postoperative complications, length of hospital stay, and reinterventions were more frequent in the bypass groups. Conclusions: In this nonrandomized study, autologous vein bypass was superior to both PTA/S and synthetic bypass in regard to amputation-free survival and overall mortality. Despite the increased frequency of surgical complications, a vein bypass appears justified in both shorter (TASC B-C) and longer (TASC D) femoropopliteal lesions.

AB - Background: The objective of the study was to compare bypass surgery and endovascular revascularization of the femoropopliteal segment in patients with peripheral arterial disease and critical limb-threatening ischemia (CLTI). Methods: This is a single-center study including patients undergoing first-time lower extremity intervention with peripheral bypass surgery or percutaneous transluminal angioplasty with or without stenting (PTA/S) of the femoropopliteal segment because of CLTI from 2011 to 2015. Based on prospective entered data from the Danish Vascular Registry, the primary end points were amputation-free survival, overall mortality, and reinterventions. Results: A total of 679 patients with CLTI were included of which 35% (n = 239) were treated with PTA/S, 54% (n = 363) with vein bypass, and 11% (n = 77) with synthetic bypass. After 3 years, amputation-free survival was significantly better with a vein bypass (41.8% [95% CI: 35–48.4]) than both PTA/S (29.7% (95% CI: 22.7–37)) and synthetic bypass (31.7% [95% CI: 19–45.1]). Overall, the endovascular-treated patients faced more than 50% increased risk of major amputation or death than that of a vein bypass, after adjusting for comorbidity and Trans-Atlantic Inter-Society Consensus (TASC) classification (HR: 1.56 [95% CI: 1.21–2.05]). As expected, postoperative complications, length of hospital stay, and reinterventions were more frequent in the bypass groups. Conclusions: In this nonrandomized study, autologous vein bypass was superior to both PTA/S and synthetic bypass in regard to amputation-free survival and overall mortality. Despite the increased frequency of surgical complications, a vein bypass appears justified in both shorter (TASC B-C) and longer (TASC D) femoropopliteal lesions.

U2 - 10.1016/j.avsg.2020.03.035

DO - 10.1016/j.avsg.2020.03.035

M3 - Journal article

C2 - 32234573

AN - SCOPUS:85083770246

VL - 67

SP - 437

EP - 447

JO - Annals of Vascular Surgery

JF - Annals of Vascular Surgery

SN - 0890-5096

ER -

ID: 260242441